Advantages of GLP-1 receptor agonist therapy in comorbid patients with type 2 diabetes mellitus

Koteshkova O.M., Antsiferova D.M., Antsiferov M.B.

1) Endocrinology Dispensary of the Moscow Healthcare Department, Moscow, Russia; 2) Russian Medical Academy of Continuous Professional Education, Moscow, Russia

The number of patients with type 2 diabetes mellitus (DM2) and comorbid conditions is steadily increasing worldwide. For patients with DM2, achieving target carbohydrate metabolism parameters is important, as is weight loss, improving blood lipid profiles and blood pressure, and optimizing the course of comorbid conditions. The most commonly discussed comorbid conditions are lower extremity peripheral arterial disease (LEPAD), cardiovascular disease (CVD), metabolic-associated fatty liver disease (MAFLD), and diabetic kidney disease (DKD). Improved carbohydrate metabolism, weight loss, and reduced progression of cardiovascular disease, LEAD, MAFLD, and DKD can be achieved with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 agonist). Semaglutide has demonstrated high efficacy in correcting glycemic and lipid profiles, as well as reducing body weight and blood pressure. Multicenter clinical trials have demonstrated its pronounced cardio-nephro-hepatoprotective effects, as well as a significant reduction in the risk of developing and progressing micro- and macrovascular complications.

For citations: Koteshkova O.M., Antsiferova D.M., Antsiferov M.B. Advantages of GLP-1 receptor agonist therapy in comorbid patients with type 2 diabetes mellitus. Pharmateca. 2025;32(8):34-43. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2025.8.34-43

Authors’ contribution: Koteshkova O.M. – writing, literature review, editing. Antsiferova D.M. – writing, literature review, editing. Antsiferov M.B. – editing, approval of the final version of the article.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship. 
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.

Keywords

About the Authors

O.M. Koteshkova, Cand. Sci. (Med.), Head of the Diabetes Education and Treatment Department, Endocrinology Dispensary of the Moscow Healthcare Department, Moscow, Russia; koala58@mail.ru, ORCID: https://orcid.org/0000-0001-8428-4116, eLibrary SPIN: 6141-1224 (corresponding author)
D.M. Antsiferova, Endocrinologist, Endocrinology Dispensary of the Moscow Healthcare Department, Moscow, Russia; Postgraduate Student, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; cifrenda@yandex.ru, ORCID: https://orcid.org/0000-0002-3920-5914
M.B. Antsiferov, Dr. Sci. (Med.), Professor, President, Endocrinology Dispensary of the Moscow Healthcare Department, Moscow, Russia; antsiferov@rambler.ru, ORCID: https://orcid.org/0000-0002-9944-2997, eLibrary SPIN: 1035-4773

Similar Articles